Stereotactic ablative radiotherapy for patients during COVID-19 pandemic

In June 2020, NHS England announced in June 2020 that it is accelerating the use of stereotactic ablative radiotherapy (SABR) requiring fewer doses than standard radiotherapy, decreasing the number of hospital visits that potentially vulnerable patients need to undergo. It will now be available through the NHS by the end of the current financial year, rather than full rollout by 2022.

It is a very accurate method of using a high dose of radiation with only about five outpatient visits compared to conventional radiotherapy, requiring between 20 and 30 treatments.

SABR treatment for non-small cell lung cancer and those with lung, lymph nodes, and non-spine bone oligometastatic disease will be offered to all parts of the country in radiotherapy units nationwide. A further rollout for other types of diseases is planned for 2021/22.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.